Ftse Mib
35.402,26
-0,02%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.894,99
2,54%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ PepGen Inc (PEPG) PepGen Inc (PEPG) Notizie

PEPG

PepGen (PEPG)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PEPG
DataOraFonteTitoloSimboloCompagnia
17/05/202422:33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PEPGPepGen Inc
14/05/202422:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PEPGPepGen Inc
14/05/202422:02GlobeNewswire Inc.PepGen Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:PEPGPepGen Inc
14/05/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
13/03/202421:05GlobeNewswire Inc.PepGen to Participate in Upcoming Investor ConferencesNASDAQ:PEPGPepGen Inc
13/03/202412:00GlobeNewswire Inc.PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyNASDAQ:PEPGPepGen Inc
06/03/202422:23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PEPGPepGen Inc
06/03/202422:01GlobeNewswire Inc.PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:PEPGPepGen Inc
04/03/202413:00GlobeNewswire Inc.PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyNASDAQ:PEPGPepGen Inc
01/03/202423:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PEPGPepGen Inc
20/02/202414:00GlobeNewswire Inc.PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1NASDAQ:PEPGPepGen Inc
07/02/202422:55Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PEPGPepGen Inc
07/02/202413:30GlobeNewswire Inc.PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common StockNASDAQ:PEPGPepGen Inc
17/01/202413:00GlobeNewswire Inc.Mary Beth DeLena Joins PepGen as General Counsel and SecretaryNASDAQ:PEPGPepGen Inc
08/01/202413:00GlobeNewswire Inc.PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 SkippingNASDAQ:PEPGPepGen Inc
18/12/202314:00GlobeNewswire Inc.PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)NASDAQ:PEPGPepGen Inc
15/11/202314:00GlobeNewswire Inc.PepGen Announces Appointment of Howard Mayer, M.D. to Board of DirectorsNASDAQ:PEPGPepGen Inc
08/11/202314:00GlobeNewswire Inc.PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:PEPGPepGen Inc
12/10/202313:52Dow Jones NewsFDA Lifts Hold on PepGen's New Drug Application for Dystrophy TreatmentNASDAQ:PEPGPepGen Inc
12/10/202313:00GlobeNewswire Inc.PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)NASDAQ:PEPGPepGen Inc
27/09/202322:16GlobeNewswire Inc.PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of NeurologyNASDAQ:PEPGPepGen Inc
06/09/202322:05GlobeNewswire Inc.PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1NASDAQ:PEPGPepGen Inc
06/09/202314:00GlobeNewswire Inc.PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical ConferencesNASDAQ:PEPGPepGen Inc
01/09/202314:00GlobeNewswire Inc.PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:PEPGPepGen Inc
08/08/202314:15GlobeNewswire Inc.PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:PEPGPepGen Inc
26/06/202322:17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PEPGPepGen Inc
22/06/202322:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PEPGPepGen Inc
13/06/202323:07Dow Jones NewsPepGen Withdraws Guidance on Launch of Study for Muscle Disease TreatmentNASDAQ:PEPGPepGen Inc
13/06/202322:05GlobeNewswire Inc.PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1NASDAQ:PEPGPepGen Inc
02/06/202322:12Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:PEPGPepGen Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PEPG

La tua Cronologia

NYSE
NMFC
New Mountain Finance
AMEX
XTE
TG
4OR1
Organovo
LSE
0KYY
S&p Global
COIN
CREEUR
USOTC
ITDN
Interdyne (CE)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network